{
    "title": "Novartis sees steady growth as weighs selling generics arm",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-10467179/Novartis-forecasts-2022-sales-profit-growth-Sandoz-review-continues.html",
    "date": "2022-02-02",
    "keywords": [
        "core",
        "interest",
        "sandoz",
        "drug",
        "burger",
        "operating",
        "profit",
        "year",
        "business",
        "novartis",
        "end",
        "quarter",
        "income",
        "increase",
        "forecast",
        "line",
        "drugmaker",
        "company",
        "prospect",
        "october",
        "price",
        "sector",
        "update",
        "matter",
        "equity",
        "valuation",
        "executive",
        "vas",
        "narasimhan",
        "wednesday",
        "table",
        "bias",
        "moment",
        "work",
        "carveout",
        "finance",
        "chief",
        "harry",
        "progress",
        "marketing",
        "development",
        "gmt",
        "trading",
        "bridge",
        "zuercher",
        "kantonalbank",
        "guidance",
        "digit",
        "growth",
        "arthritis",
        "psoriasis",
        "cosentyx",
        "refinitiv",
        "heart",
        "failure",
        "treatment",
        "entresto",
        "market",
        "consensus",
        "singledigit",
        "rate",
        "worth",
        "spending",
        "power",
        "research",
        "dividend",
        "share",
        "creation",
        "louise",
        "mark",
        "potter"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}